Navigation Links
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
Date:11/11/2009

f 2008, primarily as a result of expenses in 2008 related to Oncothyreon's reincorporation in the United States and fewer personnel in 2009.

Total revenue was $4,000 and $39,000, respectively, for the three and nine months ended September 30, 2009, compared to $0.8 million and $4.0 million for the same periods in 2008. The decrease in revenue was primarily the result of the transfer of manufacturing of Stimuvax to Merck KGaA in December 2008.

Oncothyreon reported a net loss of $5.9 million, or $0.24 per basic and diluted share, for the three months ended September 30, 2009, compared with a net loss of $3.6 million, or $0.18 per basic and diluted share, for the comparable period in 2008. The net loss for the third quarter of 2009 includes a $3.2 million non-cash charge for the change in the fair value of warrants issued in connection with its May 2009 securities offering. Oncothyreon reported a net loss of $14.7 million, or $0.68 per basic and diluted share, for the nine months ended September 30, 2009, compared with a net loss of $13.6 million, or $0.70 per basic and diluted share, for the comparable period in 2008. The net loss for the nine-month period includes $5.7 million in non-cash charges related to the change in the fair value of warrant liability.

As of September 30, 2009, Oncothyreon's cash and cash equivalents were $35.0 million, compared to $19.2 million at the end of 2008, an increase of $15.8 million, or 82.3 percent. Major contributors to the net change included net proceeds of approximately $24.2 million from the sale of shares of Oncothyreon's common stock and warrants to purchase shares of Oncothyreon's common stock in 2009 offset by $8.4 million used for operating and capital expenditures in the first nine months of 2009.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. Oncothyreon is providing this guidance as a convenience to i
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces webcast of third quarter 2009 financial results conference call
2. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
3. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
4. Oncothyreon reports second quarter 2009 financial results
5. Oncothyreon announces closing of $15.0 million registered direct financing
6. Oncothyreon announces webcast of second quarter 2009 financial results conference call
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
9. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
10. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
11. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... of significant technological challenges in their quest to ... for the James Webb Space Telescope. , The ... scientist at NASA,s Goddard Space Flight Center in ... arrays that is, those activated by applying ... the current technology,s magnetically activated arrays. This advance ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... are quickly eliminated from the body. Scientists at the ... a kind of molecular balloon that swells and thus ... The TUM spin-off XL-protein GmbH has now started to ... People who suffer from hepatitis B are often treated ...
... WOBURN, Mass., Sept. 21 The Center for Business Intelligence ... the proceeds from their Alzheimer,s Drug Development Summit to the ... this week, September 21-25, 2009, in recognition of World Alzheimer,s ... Alzheimer,s associations, globally, to raise awareness and encourage citizens to ...
... NEW YORK, Sept. 21 Emissary Capital Group, ... (OTC Bulletin Board: SNBP) with a Buy rating and ... domestically as Dong Ying Pharmaceutical Co. Ltd., is a ... R&D, manufacture and distribution of biopharmaceutical products. The ...
Cached Biology Technology:Researchers prolong the plasma half-life of biopharmaceutical proteins 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 3Emissary Capital Group Initiates Coverage on Sinobiopharma 2
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... Steven Chown has been awarded the Scientific Committee ... in Antarctic Research. , SCAR, an inter-disciplinary international ... international scientific research in the Antarctic region, and ... the Earth system. The organisation also provides scientific ... responsible for governing the region. , The medal ...
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2
... Harnessing the strength of a natural process that ... from UT Southwestern Medical Center has helped establish ... and permanently correct mutations in disease-causing genes. , ... By artificially initiating a DNA repair process known ...
... Scientists studying mice have identified a gene that allows ... the inflammatory chemicals they secrete. , Researchers at Washington ... knocking the gene out in mice prevented the development ... of their own damaging secretions. , The newly identified ...
... by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, ... Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer ... label Human Immunodeficiency Viruses (HIV) for visual investigations ... , The labeling permits scientists to observe the ...
Cached Biology News:Researchers pioneer new gene therapy technique using natural repair process 2Researchers pioneer new gene therapy technique using natural repair process 3Disabling gene defuses rheumatoid arthritis in mice 2Disabling gene defuses rheumatoid arthritis in mice 3New Species of Coral Discovered Off Southern California 2
Request Info...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
... 96 Well BAC Prep; Ideal ... from 1.5ml 2xYT cultures; Provides ... fluorescent sequencing for small to ... strategy which minimizes shearing and ...
Biology Products: